PI3K / Akt / mTOR

Category
  1. Akt (29)
  2. PI3K (80)
  3. mTOR (34)
  4. PDK1 (9)
  5. DNA-PK (6)
  6. RSK (6)
Target
  1. DNA-PK (1)
  2. p110α (6)
  3. p110β (2)
  4. p110δ (2)
  5. p110γ (2)
Actions
  1. Activator (1)
  2. Inhibitor (121)


Items 1 to 25 of 150 total

per page
Page:
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5

Set Descending Direction
Catalog No. Product Name Product Information
A13590

10-DEBC HCl

10-DEBC HCl is a selective inhibitor of Akt/PKB. It inhibits IGF-1-stimulated phosphorylation and activation of Akt (complete inhibition at 2.5 ??M), suppressing downstream activation of mTOR, p70 S6 kinase and S6 ribosomal protein.
A11151

3-Methyladenine

3-Methyladenine is an inhibitor of class III phosphatidylinositol 3-kinase (PI 3-kinase).
A11287

A-443654

A-443654, a specific Akt inhibitor, interferes with mitotic progression and bipolar spindle formation.
A11034

A-674563

A-674563 is a B/Akt inhibitor with an IC50 of 14 nM and also shows inhibitory activity against PKA and CDK2 with IC50 of 16 and 46 nM, respectively.
A11202

A66

The S-enantiomer of A66 is a potent inhibitor of the p110alpha isoform of PI 3-kinase (PIK3CA).
A14441

Acalisib (GS-9820)

Acalisib is an inhibitor of the beta and delta isoforms of the 110 kDa catalytic subunit of class IA phosphoinositide-3 kinases (PI3K) with potential immunomodulating and antineoplastic activities.
A13030

Afuresertib

Afuresertib, also known as GSK2110183, is an orally bioavailable inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic activity. It binds to and inhibits the activity of Akt, which may result in inhibition of the PI3K/Akt signaling pathway and tumor cell proliferation and the induction of tumor cell apoptosis. Activation of the PI3K/Akt signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K/Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents.
A11286

AKT inhibitor VIII (AKTI-1/2)

AKT inhibitor VIII is a cell-permeable and reversible quinoxaline compound that potently and selectively inhibits Akt1/Akt2 activity (IC50 = 58 nM, 210 nM, and 2.12 ?M for Akt1, Akt2, and Akt3, respectively, in in vitro kinase assays).
A16285

Akt1 and Akt2-IN-1

Akt1 and Akt2-IN-1 is an allosteric inhibitor of Akt1 (IC50 = 3.5 nM) and Akt2 (IC50 = 42 nM), with potent and balanced activity.
A15901

AMG319

AMG319 is a potent and selective PI3K?? inhibitor with IC50 of 18 nM, >47-fold selectivity over other PI3Ks. Phase 2.
A16286

ARQ-092

ARQ 092 is an oral activie, potent and selective AKT inhibitor with IC50 values: 5.0 nM (AKT1); 4.5 nM (AKT2); 16 nM (AKT3).
A11099

AS-252424

AS-252424 is a potent inhibitor of PI3K with selectivity for the γ isoform. It inhibits human recombinant PI3Kγ, α, β, and δ with IC50 values of 30, 940, 20,000, and 20,000 nM respectively.
A11197

AS-604850

AS-604850 inhibited MCP-1-mediated monocyte chemotaxis with an IC50 value of 21 µM and reduced RANTES-induced peritoneal neutrophil recruitment in a murine model of leukocyte chemotaxis with an ED50 value of 42.4 mg/kg.

A10088

AS-605240

AS-605240 is an orally active inhibitor of PI3-kinase γ that inhibits human recombinant PI3Kγ, α, β, and δ in an ATP-competitive manner with IC50 values of 8, 60, 270, and 300 nM, respectively.
A10094

AT7867

AT7867 is a novel and potent inhibitor of both AKT and the downstream kinase p70 S6 kinase (p70S6K) and also of protein kinase A.
A15006

AT7867 2HCl

AT7867 dihydrochloride is a potent ATP-competitive inhibitor of Akt1/2/3 and p70S6K/PKA with IC50 of 32 nM/17 nM/47 nM and 85 nM/20 nM, respectively, little activity outside the AGC kinase family.
A11303

AZD2014

AZD2014 is an orally bioavailable inhibitor of the mammalian target of rapamycin (mTOR) with potential antineoplastic activity. mTOR kinase inhibitor.
A11759

AZD5363

AZD5363 is a potent inhibitor of AKT with pharmacodynamic activity in vivo, has potential to treat a range of solid and hematologic tumors as monotherapy or a combinatorial agent.
A10112

AZD6482

AZD6482 is a PI3Kbeta inhibitor (IC50=0.021M) used in antithrombotic therapy.
A10114

AZD8055

AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mTOR kinase inhibitor with an IC50 of 0.8 nM.
A14164

AZD8186

AZD8186 is and inhibitor of the beta isoform of phosphoinositide-3 kinase (PI3K), with potential antineoplastic activity.
A15759

AZD8186

AZD8186 is an isoform-specific small-molecule PI3K inhibitor, potently inhibits PI3K?? (IC50=4 nM) and PI3K?? (IC50=12 nM) with selectivity over PI3K?? (IC50=35 nM) and PI3K?? (IC50=675 nM).
A11766

BAY 80-6946 (Copanlisib)

BAY 80-6946 is a phosphoinositide 3-kinase (PI3K) inhibitor with potential antineoplastic activity.
A10133

BEZ235 (NVP-BEZ235, Dactolisib)

BEZ235 (NVP-BEZ235) inhibits PI3K and mTOR kinase activity by binding to the ATP-binding cleft of these enzymes.
A12452

BI-D1870

BI-D1870 is a potent and specific inhibitor of the p90 ribosomal S6 kinase (RSK) isoforms in vitro and in vivo, which inhibits RSK1, RSK2, RSK3 and RSK4 in vitro with an IC50 of 10–30 nM.

Items 1 to 25 of 150 total

per page
Page:
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5

Set Descending Direction